These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16966523)

  • 1. Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease.
    Fox SH; Visanji NP; Johnston TH; Gomez-Ramirez J; Voon V; Brotchie JM
    Arch Neurol; 2006 Sep; 63(9):1343-4. PubMed ID: 16966523
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Visanji NP; Gomez-Ramirez J; Johnston TH; Pires D; Voon V; Brotchie JM; Fox SH
    Mov Disord; 2006 Nov; 21(11):1879-91. PubMed ID: 16960862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
    Silverdale MA; Nicholson SL; Ravenscroft P; Crossman AR; Millan MJ; Brotchie JM
    Exp Neurol; 2004 Jul; 188(1):128-38. PubMed ID: 15191809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.
    Bibbiani F; Costantini LC; Patel R; Chase TN
    Exp Neurol; 2005 Mar; 192(1):73-8. PubMed ID: 15698620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys.
    Bélanger N; Grégoire L; Bédard PJ; Di Paolo T
    Neurobiol Aging; 2006 Nov; 27(11):1684-93. PubMed ID: 16253392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative evaluation of MPTP-treated nonhuman parkinsonian primates in the HALLWAY task.
    Campos-Romo A; Ojeda-Flores R; Moreno-Briseño P; Fernandez-Ruiz J
    J Neurosci Methods; 2009 Mar; 177(2):361-8. PubMed ID: 19022292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.
    Smith LA; Jackson MJ; Johnston L; Kuoppamaki M; Rose S; Al-Barghouthy G; Del Signore S; Jenner P
    Clin Neuropharmacol; 2006; 29(3):112-25. PubMed ID: 16772809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy.
    van Vliet SA; Blezer EL; Jongsma MJ; Vanwersch RA; Olivier B; Philippens IH
    Brain Res; 2008 Jan; 1189():219-28. PubMed ID: 18076869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striatal histone modifications in models of levodopa-induced dyskinesia.
    Nicholas AP; Lubin FD; Hallett PJ; Vattem P; Ravenscroft P; Bezard E; Zhou S; Fox SH; Brotchie JM; Sweatt JD; Standaert DG
    J Neurochem; 2008 Jul; 106(1):486-94. PubMed ID: 18410512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effects of Delta9-THC and modafinil in a marmoset Parkinson model.
    van Vliet SA; Vanwersch RA; Jongsma MJ; Olivier B; Philippens IH
    Eur Neuropsychopharmacol; 2008 May; 18(5):383-9. PubMed ID: 18222654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
    Katzenschlager R; Jackson MJ; Rose S; Stockwell K; Tayarani-Binazir KA; Zubair M; Smith LA; Jenner P; Lees AJ
    Mov Disord; 2007 Apr; 22(5):715-9. PubMed ID: 17373723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
    Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
    Hill MP; Ravenscroft P; McGuire SG; Brotchie JM; Crossman AR; Rochat C; Millan MJ
    Mov Disord; 2006 Dec; 21(12):2090-5. PubMed ID: 16991143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Samadi P; Grégoire L; Rouillard C; Bédard PJ; Di Paolo T; Lévesque D
    Ann Neurol; 2006 Feb; 59(2):282-8. PubMed ID: 16437566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly potent activity of (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in animal models of Parkinson's disease.
    Ardashov OV; Pavlova AV; Il'ina IV; Morozova EA; Korchagina DV; Karpova EV; Volcho KP; Tolstikova TG; Salakhutdinov NF
    J Med Chem; 2011 Jun; 54(11):3866-74. PubMed ID: 21534547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protocol for the MPTP mouse model of Parkinson's disease.
    Jackson-Lewis V; Przedborski S
    Nat Protoc; 2007; 2(1):141-51. PubMed ID: 17401348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of MPTP in Parkinson's disease: connecting brain and gut?
    Goetze O; Woitalla D
    Exp Neurol; 2008 Apr; 210(2):281-5. PubMed ID: 18279853
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.